Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts

Luminal androgen receptor (LAR) breast cancer accounts for 10% of all triple-negative breast cancers (TNBC). Anti-androgen therapy for this subtype is in development, but yields only partial clinical benefits. In this study, we aimed to characterize the genomic alterations of LAR TNBC, to analyze ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Coussy, Florence, Lavigne, Marion, de Koning, Leanne, Botty, Rania El, Nemati, Fariba, Naguez, Adnan, Bataillon, Guillaume, Ouine, Berengère, Dahmani, Ahmed, Montaudon, Elodie, Painsec, Pierre, Chateau-Joubert, Sophie, Laetitia, Fuhrmann, Larcher, Thibaut, Vacher, Sophie, Chemlali, Walid, Briaux, Adrien, Melaabi, Samia, Salomon, Anne Vincent, Guinebretiere, Jean Marc, Bieche, Ivan, Marangoni, Elisabetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993232/
https://www.ncbi.nlm.nih.gov/pubmed/32042320
http://dx.doi.org/10.7150/thno.36182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993232/
https://www.ncbi.nlm.nih.gov/pubmed/32042320
http://dx.doi.org/10.7150/thno.36182

Ejemplares similares